New hope for IgG4 patients: which drug combo works best?

NCT ID NCT05789030

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two treatment plans for people with IgG4-related disease affecting superficial organs like glands or skin. One group gets prednisone plus iguratimod, the other gets prednisone plus leflunomide. Over 12 months, researchers will track how many patients have a relapse and how long it takes for symptoms to return. The goal is to find a safer, more effective way to keep the disease under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: prednisone plus iguratimod or prednisone plus leflunomide
What this could lead to: If successful, this could identify a more effective and safer drug combination to control IgG4-related disease and reduce relapses.
What could go wrong: This is a small, early-stage trial with only 60 participants, so results may not apply to all patients. Both treatments involve steroids and immune-suppressing drugs, which can have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.